Back to Authors

Padala, Prasad R.

https://orcid.org/0000-0003-1921-9806

Mayo Clinic

Central Arkansas Veterans Healthcare System

Citations 2

Apathy associated with neurocognitive disorders: Recent progress and future directions
Lanctôt, Krista L. , Agüera-Ortíz, Luis , Brodaty, Henry , Francis, Paul T. , Geda, Yonas E. , Ismail, Zahinoor , Marshall, Gad A. , Mortby, Moyra E. , Onyike, Chiadi U. , Padala, Prasad R. , Politis, Antonios , Rosenberg, Paul B. , Siegel, Emma , Sultzer, David L. , Abraham, Eleenor H , Lanctôt, Krista L , Brodaty, Henry , Geda, Yonas E

Alzheimer's & Dementia | June 28, 2016 | Volume: 13 | Issue: 1 | Pages: 84-100

10.1016/j.jalz.2016.05.008 Get It

Abstract Introduction Apathy is common in neurocognitive disorders (NCDs) such as Alzheimer's disease and mild cognitive impairment. Although the definition of apathy is inconsistent in the literature, apathy is primarily defined as a loss of motivation and decreased interest in daily activities. Methods The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) Neuropsychiatric Syndromes Professional Interest Area (NPS‐PIA) Apathy workgroup reviewed the latest research regarding apathy in NCDs. Results Progress has recently been made in three areas relevant to apathy: (1) phenomenology, including the use of diagnostic criteria and novel instruments for measurement, (2) neurobiology, including neuroimaging, neuropathological and biomarker correlates, and (3) interventions, including pharmacologic, nonpharmacologic, and noninvasive neuromodulatory approaches. Discussion Recent progress confirms that apathy has a significant impact on those with major NCD and those with mild NCDs. As such, it is an important target for research and intervention.
Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Yonas E. , Schneider, Lon S. , Gitlin, Laura N. , Smith, Gwenn S. , Evans, Jovier D., Lee, Michael K. , Porsteinsson, Anton P. , Lanctôt, Krista L. , Rosenberg, Paul B. , Sultzer, David L. , Francis, Paul T. , Brodaty, Henry , Padala, Prasad P., Onyike, Chiadikaobi, Ortiz, Luis Agüera, Vitiello, Michael V. , Yaffe, Kristine , Zee, Phyllis C. , Herrmann, Nathan , Ballard, Clive , Khin, Ni A. , Alfaro, Cara L., Murray, Patrick S. , Schultz, Susan K. , Lyketsos, Constantine G. , ISTAART, Neuropsychiatric Syndromes Professional Interest Area of, Miller, David S. , Bell, J. Simon , Padala, Prasad R. , Ancoli‐Israel, Sonia , Bliwise, Donald L. , Martin, Jennifer L. , Sweet, Robert A. , ISTAART, Neuropsychiatric Syndromes Professional Interest Area of, Lanctôt, Krista L , Brodaty, Henry , Ballard, Clive , Geda, Yonas E

Alzheimer's & Dementia | April 4, 2013 | Volume: 9 | Issue: 5 | Pages: 602-608

10.1016/j.jalz.2012.12.001 Get It

Abstract Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling. This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented with emotional distress and delusions of infidelity/excessive jealousy, followed by cognitive symptoms. Being cognizant of this, in 2010 the Alzheimer's Association convened a research roundtable on the topic of NPS in AD. A major outcome of the roundtable was the founding of a Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART). The NPS‐PIA has prepared a series of documents that are intended to summarize the literature and provide more detailed specific recommendations for NPS research. This overview paper is the first of these living documents that will be updated periodically as the science advances. The overview is followed by syndrome‐specific synthetic reviews and recommendations prepared by NPS‐PIA workgroups on depression, apathy, sleep, agitation, and psychosis.